We report data obtained from a retrospective multicenter pediatric survey on behalf of the European Society for Blood and Marrow Transplantation (EBMT). Information on solid organ transplantation (SOT) performed in pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was collected in 20 pediatric EBMT Centers (25.6%). Overall, we evaluated data on 44 SOTs following HSCT including 20 liver (LTx), 12 lung (LuTx), 6 heart (HTx), and 6 kidney (KTx) transplantations. The indication for SOT was organ failure related to intractable graft-vs-host disease in 16 children (36.3%), acute or chronic HSCT-related toxicity in 18 (40.9%), and organ dysfunction related to the underlying disease in 10 (22.8%). The median follow-up was 10.9 years (95% confidence interval: 1.7-29.5). The overall survival rate at 1 and 5 years after SOT was 85.7% and 80.4%, respectively: it was 74% and 63.2% after LTx, 83.2% after HTx, and 100% equally after LuTx and KTx. This multicenter survey confirms that SOT represents a promising option in children with severe organ failure occurring after HSCT. Additional studies are needed to further establish the effectiveness of SOT after HSCT and to better understand the mechanism underlying this encouraging success.

Clinic of Pediatric Hemato Oncology Department of Women's and Children's Health University Hospital of Padova Padova Italy

Department for Children and Adolescents Division for Stem Cell Transplantation and Immunology University Hospital Frankfurt Frankfurt am Main Germany

Department for Children and Adolescents Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Department of Pediatric Oncology and Hematology Hospital Universitario Vall d'Hebron Barcelona Spain

Department of Pediatrics Jena University Hospital Jena Germany

Department of Pediatrics Stem Cell Transplantation Program Leiden University Medical Center Leiden The Netherlands

Department of Pediatrics University Medical Center Ulm Germany

Department Pediatric Hematology Oncology Hemostaseology Universitätsklinikum Leipzig Leipzig Germany

Dipartimento di Onco Ematologia Pediatrica IRCSS Ospedale Pediatrico Bambino Gesù Rome Italy

Division of Stem Cell Transplantation and Regenerative Medicine Department of Pediatrics School of Medicine Stanford University Stanford California

European Society for Blood and Marrow Transplantation Pediatric Disease Working Party Paris France

Hematology Oncology and Stem Cell Transplantation Department of Pediatrics Hôpital Hautepierre Strasbourg France

Hematopoietic Stem Cell Transplantation Unit Hematology Oncology Istituto G Gaslini Genova Italy

Institute of Cellular Medicine Pediatric Immunology Department Newcastle University Great North Children's Hospital Newcastle upon Tyne UK

Instute Portugues Oncologia Lisboa Lisboa Portugal

Pediatric Blood and Marrow Transplantation Program Laboratory for Translational Immunology Tumor immunology University Medical Center Utrecht The Netherlands

Pediatric Hematology and Oncology University Hospital Münster Muenster Germany

Pediatric Hematopoietic Transplant Unit Sant Pau Hospital Barcelona Spain

Service of Pediatric Hematology Oncology Hôpital Armand Trousseau Paris France

St Anna Children's Hospital Medical University of Vienna Vienna Austria

Stem Cell Transplant and Cellular Therapies Pediatrics Memorial Sloan Kettering Cancer Center New York New York

Unidad de Hematología y Oncología Pediátrica Hospital Universitario La Paz Madrid Spain

University Hospital Eppendorf Hamburg Germany

University Hospital Motol Prague Czech Republic

Citace poskytuje Crossref.org